Nacimbio presents its key projects and new R&D

| By | FORT, Microgen, Nacimbio, R&D, Sintez

Nacimbio, a pharmaceutical holding company of Rostec Corporation, takes part in PharmMedProm-2017 exhibition held during the Russian Health Care Week. The company presents its key projects, new promising R&D and well-known products with good sales in the public sector and on the commercial market.

“This year, the exposition of the company turned into an interactive platform where the holding company and its key industrial enterprises can showcase their products and innovation,” said Andrey Zagorsky, the General Director of Nacimbio.

FORT LLC, the latest manufacturing site of Nacimbio, demonstrates its flu vaccines in Ultrix and Sovigripp, the pre-filled syringes supplied for the public immunization under the National Immunization Calendar.

The visitors also have the opportunity to see new R&D of Sintez JSC. The plastic blood bags, that have no analogs in Russia, were registered in October 2017 and will be available in the market as early as next year. disposable bags make the process of donor blood collection safer and easier both for the patients and health professionals. The new devices are the first Russian-made blood bags that allow to obtain leukocyte-reduced donor blood and lower the risk of complications in patients.

NPO Microgen, the largest Russian manufacturer of immunobiological medicines, presents at this joint exhibition 14 monophagous and polyphagous agents for the treatment of infectious diseases. Difag and Enterobacter, the new products of the holding company, are at the stage of clinical trials. Difag will be used to fight Acinetobacter bacteria and Pseudomonas aeruginosa, while Enterobacter will, for the first time in the world, combine the entire complex of bacteriophages of Enterobacter species. Such medicine is effective for the treatment of acute intestinal diseases, infections of biliary tract and urinary tract, purulent damage of skin and meninx, sepsis, hospital-acquired infections.

“Amid the increasing antibiotic resistance, fagotherapy has great prospects in the fight against bacterial infections. This year, the bacteriophages were included in the implementation of the Strategy for Preventing the Spread of Antimicrobial Resistance in the Russian Federation until 2030 initiated by WHO in all countries,” said Kirill Gaidash, the General Director of NPO Microgen.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.